Investment analysts at Morgan Stanley started coverage on shares of Radius Health (NASDAQ:RDUS) in a report released on Monday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $57.00 price target on the biopharmaceutical company’s stock. Morgan Stanley’s target price would suggest a potential upside of 43.22% from the company’s previous close.
Several other research firms also recently weighed in on RDUS. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 target price on shares of Radius Health in a research report on Friday, October 6th. Citigroup reissued a “hold” rating and set a $43.00 target price on shares of Radius Health in a research report on Monday, January 22nd. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $58.00 target price on shares of Radius Health in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. Radius Health has a consensus rating of “Hold” and an average price target of $50.75.
Radius Health (RDUS) traded up $1.06 during midday trading on Monday, hitting $39.80. The stock had a trading volume of 625,313 shares, compared to its average volume of 965,963. The company has a market cap of $1,727.49, a P/E ratio of -7.52 and a beta of 1.10. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health has a 52-week low of $24.66 and a 52-week high of $49.16.
In other Radius Health news, VP Brent Hatzis-Schoch acquired 1,778 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was bought at an average price of $28.09 per share, for a total transaction of $49,944.02. Following the acquisition, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the acquisition, the insider now owns 5,698,799 shares in the company, valued at $149,593,473.75. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 108,578 shares of company stock valued at $3,017,416. 15.00% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of RDUS. Cubist Systematic Strategies LLC purchased a new stake in shares of Radius Health in the 3rd quarter worth $110,000. Ameritas Investment Partners Inc. raised its position in shares of Radius Health by 19.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 541 shares in the last quarter. Advisor Group Inc. raised its position in shares of Radius Health by 267.2% in the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares in the last quarter. Amalgamated Bank bought a new position in shares of Radius Health in the 2nd quarter worth $211,000. Finally, Principal Financial Group Inc. raised its position in shares of Radius Health by 14.1% in the 2nd quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 839 shares in the last quarter.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.